Early evidence links alcohol exposure with weaker anti-PD-1 responses

Regular alcohol consumption may reduce the effectiveness of a major class of cancer immunotherapies, according to research reported in Science Signaling. The study combined experiments in mice with an analysis of human clinical data and focused on immune checkpoint inhibitors that target programmed cell death protein 1, or PD-1.

The finding is consequential because anti-PD-1 medicines are used across several advanced cancers. These treatments are designed to help the immune system recognize and attack tumor cells. But the new work suggests that an everyday exposure—alcohol—could be associated with a reduced treatment benefit.

The evidence remains early. The animal results do not establish what will happen in every patient, and the human observations described in the report do not by themselves prove that alcohol caused poorer outcomes. Still, the alignment between the mouse experiments and the clinical-data pattern gives researchers a reason to investigate the relationship more closely.

How anti-PD-1 therapy works

T cells are immune cells that can identify and destroy cancer cells. Their activity is regulated by biological safeguards that help prevent an immune response from becoming excessive and damaging healthy tissue. PD-1 is one of the receptor systems involved in that regulation.

Cancer cells can exploit this system by activating the PD-1 pathway, effectively suppressing the T-cell response that might otherwise attack a tumor. Anti-PD-1 drugs use engineered antibodies to bind the PD-1 receptor and block that suppressive signal. In simplified terms, the medicines are intended to release a brake on T cells.

Alcohol may weaken cancer immunotherapy, early research suggests
Model of alcohol inhibition of anti-PD1 efficacy. Credit: Science Signaling (2026). DOI: 10.1126/scisignal.aef1375

Drugs in this category include pembrolizumab and nivolumab. Their effectiveness can vary substantially between people and cancer types, making it important to understand factors that may influence treatment response.

What the researchers observed in mice

In mouse models of lung and bladder cancer, moderate-to-heavy alcohol consumption was associated with markedly poorer immunotherapy performance. The report said alcohol exposure cut the success of immunotherapy by nearly half and increased the likelihood that tumors would return.

The researchers also found that alcohol reduced the number of tumor-infiltrating T cells and impaired cancer-killing activity. Tumor-infiltrating T cells are especially relevant in this setting because they are immune cells that have entered the tumor environment, where checkpoint therapy is meant to help restore an anti-cancer response.

Those results provide a potential biological explanation for the weaker treatment response observed in the animal models: alcohol exposure appeared to affect both the immune cells reaching tumors and their ability to kill cancer cells.

Human data showed a similar pattern

The study also examined clinical data from people with lung cancer receiving anti-PD-1 treatment. Patients described as regularly consuming alcohol—more than one drink per week in the report—experienced fewer survival benefits after treatment began than patients who did not fit that description.

That association is notable, but it needs careful interpretation. Clinical data can reveal patterns without resolving all the reasons behind them. Differences between patient groups may include factors beyond alcohol use, and the reported findings do not establish a universal threshold that applies to every person or treatment plan.

Alcohol may weaken cancer immunotherapy, early research suggests
Individual tumor growth curves from mice receiving anti-PD1 and anti-TIGIT treatment. Credit: Science Signaling (2026). DOI: 10.1126/scisignal.aef1375

Even so, the consistency of the direction of the results across the mouse work and the human-data analysis is what makes the research worth attention. It raises the possibility that alcohol use may be a modifiable factor affecting an immune treatment’s chances of success.

Why the work matters now

Immune checkpoint inhibitors have changed care for several advanced cancers, but they do not work equally well for all patients. Research that identifies influences on response could help clinicians and patients have more informed conversations during treatment.

The immediate takeaway is not that patients should change treatment or make health decisions based on one study. Cancer care is highly individual, and the source report characterizes this as early research. People receiving immunotherapy should discuss alcohol use, treatment expectations, and any changes to their routine with their oncology team.

For researchers, the next questions are clear: whether the association can be confirmed in larger and more diverse patient groups, how alcohol affects immune activity around tumors, and whether timing or level of exposure changes the effect. Answers could help clarify whether alcohol use should become a routinely considered factor in anti-PD-1 treatment planning.

For now, the study adds a new variable to the growing effort to understand why checkpoint immunotherapy succeeds in some cases and falls short in others.

This article is based on reporting by Medical Xpress. Read the original article.

Originally published on medicalxpress.com